News | April 05, 2021
Zydus seeks DCGI approval for the use of Pegylated Interferon alpha-2b in treating COVID-19
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
The vaccine was 85 percent effective in preventing severe disease across all regions.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Bharat Biotech expects to share further details of the trial results as additional data become available.
The company will review FDA's response and decide on appropriate next steps soon.
Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
